These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33062157)

  • 1. Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors.
    Tsang JE; Urner LM; Kim G; Chow K; Baufeld L; Faull K; Cloughesy TF; Clark PM; Jung ME; Nathanson DA
    ACS Med Chem Lett; 2020 Oct; 11(10):1799-1809. PubMed ID: 33062157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting Blood-Brain Barrier Permeation of Erlotinib and JCN037 by Molecular Simulation.
    Liang Y; Zhi S; Qiao Z; Meng F
    J Membr Biol; 2023 Apr; 256(2):147-157. PubMed ID: 36441253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of epidermal growth factor receptor-tyrosine kinase inhibitors in the management of central nervous system metastases in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer patients.
    Batra U; Lokeshwar N; Gupta S; Shirsath P
    Indian J Cancer; 2017 Dec; 54(Supplement):S37-S44. PubMed ID: 29292707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs.
    Colclough N; Chen K; Johnström P; Strittmatter N; Yan Y; Wrigley GL; Schou M; Goodwin R; Varnäs K; Adua SJ; Zhao M; Nguyen DX; Maglennon G; Barton P; Atkinson J; Zhang L; Janefeldt A; Wilson J; Smith A; Takano A; Arakawa R; Kondrashov M; Malmquist J; Revunov E; Vazquez-Romero A; Moein MM; Windhorst AD; Karp NA; Finlay MRV; Ward RA; Yates JWT; Smith PD; Farde L; Cheng Z; Cross DAE
    Clin Cancer Res; 2021 Jan; 27(1):189-201. PubMed ID: 33028591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
    Hu P; Han DX; Ruan RS; Zheng LM; Chou SH; Tzeng CM
    Oncotarget; 2016 Jun; 7(24):35741-35752. PubMed ID: 26848869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of osimertinib against EGFRvIII+ glioblastoma.
    Chagoya G; Kwatra SG; Nanni CW; Roberts CM; Phillips SM; Nullmeyergh S; Gilmore SP; Spasojevic I; Corcoran DL; Young CC; Ballman KV; Ramakrishna R; Cross DA; Markert JM; Lim M; Gilbert MR; Lesser GJ; Kwatra MM
    Oncotarget; 2020 Jun; 11(22):2074-2082. PubMed ID: 32547705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
    Ahluwalia MS; Becker K; Levy BP
    Oncologist; 2018 Oct; 23(10):1199-1209. PubMed ID: 29650684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.
    Kuang YH; Shen T; Chen X; Sodani K; Hopper-Borge E; Tiwari AK; Lee JW; Fu LW; Chen ZS
    Biochem Pharmacol; 2010 Jan; 79(2):154-61. PubMed ID: 19720054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
    Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
    Akhavan D; Pourzia AL; Nourian AA; Williams KJ; Nathanson D; Babic I; Villa GR; Tanaka K; Nael A; Yang H; Dang J; Vinters HV; Yong WH; Flagg M; Tamanoi F; Sasayama T; James CD; Kornblum HI; Cloughesy TF; Cavenee WK; Bensinger SJ; Mischel PS
    Cancer Discov; 2013 May; 3(5):534-47. PubMed ID: 23533263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib: early clinical development in brain cancer.
    Addeo R; Zappavigna S; Parlato C; Caraglia M
    Expert Opin Investig Drugs; 2014 Jul; 23(7):1027-37. PubMed ID: 24836441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer.
    Kim DH; Choi YJ; Sung KJ; Yoo SA; Sung YH; Kim JK; Choi CM; Yun M; Lee EY; Jin YS; Cook S; Rho JK; Lee JC
    Mol Oncol; 2018 Dec; 12(12):2182-2190. PubMed ID: 30350450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CR13626: a novel oral brain penetrant tyrosine kinase inhibitor that reduces tumor growth and prolongs survival in a mouse model of glioblastoma.
    Galimberti C; Piepoli T; Letari O; Artusi R; Persiani S; Caselli G; Rovati LC
    Am J Cancer Res; 2021; 11(7):3558-3574. PubMed ID: 34354860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
    Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiosynthesis and biological evaluation of
    Huang S; Han Y; Chen M; Hu K; Qi Y; Sun P; Wang M; Wu H; Li G; Wang Q; Du Z; Zhang K; Zhao S; Zheng X
    Bioorg Med Chem Lett; 2018 Apr; 28(6):1143-1148. PubMed ID: 29486966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.
    Jung HA; Woo SY; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
    Transl Lung Cancer Res; 2020 Oct; 9(5):1749-1758. PubMed ID: 33209598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
    Ding PN; Lord SJ; Gebski V; Links M; Bray V; Gralla RJ; Yang JC; Lee CK
    J Thorac Oncol; 2017 Apr; 12(4):633-643. PubMed ID: 28007626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
    Tan CS; Cho BC; Soo RA
    Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant
    Zhang Y; Zhang Y; Niu W; Ge X; Huang F; Pang J; Li X; Wang Y; Gao W; Fan F; Li S; Liu H
    Front Pharmacol; 2021; 12():750031. PubMed ID: 34630120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.